Drug intelligence / Profile preview

Magicell-NK

Development stage: Phase 2
Lead developer: Medigen Biotechnology
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Infusion, Intravenous

Overview

Magicell-NK is an autologous or allogeneic ex vivo expanded and activated Natural Killer (NK) cell therapy developed by Medigen Biotechnology Corporation. It is designed to kill cancer cells. A genetically modified version, mRNA-CAR-NK, is also in development, showing potential for enhanced cytotoxicity against gastrointestinal cancer cells without viral transfection. The drug is being investigated for various cancer indications, including colon cancer and pancreatic or bile duct cancer.

Brand names: Magicell-NKMagicell®-NK
Other names: Allogeneic Magicell-NKAllogeneic Magicell®-NKAutologous Magicell-NKAutologous Magicell®-NK

Beyond the preview

Go deeper on Magicell-NK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Magicell-NK.

Explore the full profile